Indication
Recurrent pleural malignant mesothelioma
2 clinical trials
2 drugs
Clinical trial
A Phase II Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Malignant MesotheliomaStatus: Active (not recruiting), Estimated PCD: 2026-03-20
Drug
mFOLFOX6Clinical trial
A Phase II, Single-Arm Open-Label Study of the Combination of Atezolizumab and Bevacizumab in Rare Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2025-09-30
Drug
Atezolizumab